World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia: A systematic review of longitudinal studies.

OBJECTIVE To identify the prognostic biomarker candidates for stratification and long-term surveillance of oral leukoplakia progressing to cancer via a systematic literature review. MATERIALS AND METHODS Systematic searches with no date restrictions were conducted on March 29, 2018, targeting the databases PubMed (Ovid), EMBASE (Ovid), EBM (Ovid), and Web of Science (ISI). Bias was assessed using the Quality in Prognosis Studies tool. Biomarkers were stratified based on hallmarks of cancer. RESULTS Inclusion criteria were met by 25 of 3,415 studies. A range of biomarkers were evaluated experimentally for risk stratification, prognosis, and surveillance of oral leukoplakia in tissue, blood, and saliva. However, the studies were highly heterogeneous and require further validation. Biomarkers reported in these studies included inflammatory or oxidative markers, growth factors, ion channels, genetic and cellular regulatory factors, and epigenetic biomarkers. Studies tended to include small sample sizes, under-reported or variably reported histopathological data, did not address potential confounding, reported limited/variable follow-up data, or lacked a control group. Inclusion of subsets from chemoprevention trials may have introduced bias regarding reported malignant transformation rates and accuracy of prognostic biomarkers. CONCLUSIONS This review identified insufficient longitudinal evidence to support validated prognostic biomarkers for oral leukoplakia. Further studies are needed to identify molecular targets with the potential to mitigate risk of malignant transformation.

[1]  W. Grizzle,et al.  Retinoid modulation of biomarkers in oral leukoplakia/dysplasia. , 1994, Journal of cellular biochemistry. Supplement.

[2]  Edward S. Kim,et al.  New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development , 2015, Cancer Prevention Research.

[3]  F. Visioli,et al.  Expression of the cell cycle regulation proteins p53 and p21WAF1 in different types of non-dysplastic leukoplakias , 2012, Journal of applied oral science : revista FOB.

[4]  A. Arcangeli,et al.  Potassium channels: novel emerging biomarkers and targets for therapy in cancer. , 2012, Recent patents on anti-cancer drug discovery.

[5]  Edward S. Kim,et al.  ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia , 2009, Clinical Cancer Research.

[6]  E. Bloemena,et al.  Incorporation of differentiated dysplasia improves prediction of oral leukoplakia at increased risk of malignant progression , 2020, Modern Pathology.

[7]  K. Srivastava.  Comparative Evaluation of Saliva’s Oxidant–Antioxidant Status in Patients with Different Clinicopathological Types of Oral Leukoplakia , 2019, Journal of International Society of Preventive & Community Dentistry.

[8]  T. Yen,et al.  Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer , 2012, Clinical chemistry and laboratory medicine.

[9]  S. Warnakulasuriya,et al.  Prevalence of oral potentially malignant disorders: A systematic review and meta‐analysis , 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[10]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[11]  N. Tanić,et al.  Genomic instability and tumor-specific DNA alterations in oral leukoplakias. , 2009, European journal of oral sciences.

[12]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[13]  Edward S. Kim,et al.  Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer , 2018, Journal of the National Cancer Institute.

[14]  P. Speight,et al.  Oral potentially malignant disorders: risk of progression to malignancy. , 2017, Oral surgery, oral medicine, oral pathology and oral radiology.

[15]  Yun-Shien Lee,et al.  Clincopathological characteristics and treatment outcomes of oral leukoplakia by carbon dioxide laser excision in the elderly patients , 2020, Head & neck.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  A. Villa,et al.  Leukoplakia-A Diagnostic and Management Algorithm. , 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[18]  T. Yen,et al.  Positive association of glucose‐regulated protein 78 during oral cancer progression and the prognostic value in oral precancerous lesions , 2009, Head & neck.

[19]  S. Warnakulasuriya.  Clinical features and presentation of oral potentially malignant disorders. , 2018, Oral surgery, oral medicine, oral pathology and oral radiology.

[20]  T. Axéll,et al.  Oral leukoplakia: a proposal for uniform reporting. , 2002, Oral oncology.

[21]  J. Reibel.  Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[22]  T. Taylor,et al.  Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  J. J. Lee,et al.  Loss of Heterozygosity (LOH) Profiles—Validated Risk Predictors for Progression to Oral Cancer , 2012, Cancer Prevention Research.

[24]  Xi Yang,et al.  Progress risk assessment of oral premalignant lesions with saliva miRNA analysis , 2013, BMC Cancer.

[25]  S. Lippman,et al.  Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.

[26]  P. Lequerica-Fernández,et al.  HERG1 potassium channel expression in potentially malignant disorders of the oral mucosa and prognostic relevance in oral squamous cell carcinoma , 2016, Head & neck.

[27]  Zengtong Zhou,et al.  Upregulation of miR-31* Is Negatively Associated with Recurrent/Newly Formed Oral Leukoplakia , 2012, PloS one.

[28]  Diane D. Liu,et al.  Loss of E‐cadherin and p27 expression is associated with head and neck squamous tumorigenesis , 2005, Cancer.

[29]  R. Jacobs,et al.  Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. , 2010, Journal of oral science.

[30]  W. Grizzle,et al.  Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. , 1999, Head & neck.

[31]  Y. Liu,et al.  Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. , 2014, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[32]  Li Mao,et al.  Gene Expression Profiling Predicts the Development of Oral Cancer , 2011, Cancer Prevention Research.

[33]  Masatoshi Hirayama,et al.  Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia , 2017, Cancer medicine.

[34]  P. Lequerica-Fernández,et al.  Expression of the voltage‐gated potassium channel Kv3.4 in oral leucoplakias and oral squamous cell carcinomas , 2016, Histopathology.

[35]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[36]  I. Asahina,et al.  Histopathological Change of Oral Malignant Tumour and Epithelial Dysplasia Subjected to Photodynamic Therapy , 2010, Journal of oral & maxillofacial research.

[37]  W. Grizzle,et al.  Transforming growth factor α (TGF‐α) expression in dysplastic oral leukoplakia: Modulation by 13‐cis retinoic acid , 1999 .

[38]  S. Lippman,et al.  Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  S. Warnakulasuriya,et al.  Nomenclature and classification of potentially malignant disorders of the oral mucosa. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[40]  S. Hasegawa,et al.  p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[41]  V. Bhatia,et al.  Fibroblast Growth Factor (FGF-2) and Its Receptors FGFR-2 and FGFR-3 May Be Putative Biomarkers of Malignant Transformation of Potentially Malignant Oral Lesions into Oral Squamous Cell Carcinoma , 2015, PloS one.

[42]  Edward S. Kim,et al.  Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Speight,et al.  Natural history of potentially malignant oral lesions and conditions: an overview of the literature. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.